Overactive bladder in the elderly: a guide to pharmacological management.

Area of Science:

• Geriatric Medicine
• Pharmacology
• Urology

Background:

• Overactive bladder (OAB) is a prevalent condition in the elderly, significantly impacting quality of life.
• Antimuscarinic agents are common OAB treatments, but concerns exist regarding adverse events and drug interactions in older adults.
• OAB prevalence increases with age, yet treatment is often underutilized in geriatric populations.

Purpose of the Study:

• To review the pathophysiology and diagnosis of OAB in older patients.
• To evaluate the pharmacology and clinical effects of antimuscarinic agents for OAB in the elderly.
• To provide guidance on selecting appropriate OAB treatments for geriatric patients, considering safety and efficacy.

Main Methods:

• Literature review of OAB pathophysiology, diagnosis, and treatment options.
• Analysis of antimuscarinic drug profiles, focusing on efficacy, tolerability, and safety in elderly populations.
• Comparison of drug metabolism pathways, particularly cytochrome P450 interactions, for commonly prescribed antimuscarinics.

Main Results:

• Antimuscarinics vary in structure and functional profile, impacting their suitability for elderly patients.
• Oxybutynin and tolterodine are associated with cognitive and sleep disturbances; trospium chloride and darifenacin show fewer such effects.
• Trospium chloride is not extensively metabolized by the CYP450 system, reducing the risk of drug interactions compared to other agents.

Conclusions:

• Selecting antimuscarinic therapy for elderly OAB patients requires careful consideration of CNS effects and drug interaction potential.
• Trospium chloride and darifenacin appear to have a more favorable safety profile regarding cognitive and sleep-related adverse events in the elderly.
• Trospium chloride's unique metabolic pathway offers a potential advantage in managing polypharmacy in older adults with OAB.